Business
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025. Jérôme Contami
About this update from Lakefront Biotherapeutics
[{"type":"image","alt":"Galapagos NV","displaySize":"","headline":null,"caption":"Galapagos NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n2iAy9u_uXZxYevnIzv00A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9","width":300,"height":55}},"lazy":false},{"type":"text","content":"New Directors bring deep commercial, operational, and transaction experience to the Board","length":89,"tagName":"p"},{"type":"text","content":"Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025.","length":269,"tagName":"p"},{"type":"text","content":"Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025.","length":129,"tagName":"p"},{"type":"text","content":"Jérôme Contamine, Chair of the Board, said: “We are very pleased to welcome Dawn and Jane to our Board of Directors. Their appointments further strengthen the Board and underscore our commitment to long-term value creation. On behalf of the entire Board and leadership team, I would like to sincerely thank Peter and Simon for their dedication and significant contributions over the past years. Their strategic guidance, especially during this critical period of transition, has been truly invaluable.”","length":502,"tagName":"p"},{"type":"text","content":"“We warmly welcome Dawn and Jane to the Board,” said Henry Gosebruch, CEO of Galapagos. “They bring decades of global leadership experience in our sector, with a strong track record in commercial strategy, organizational transformation, strategic transactions, and corporate governance. Their perspectives will be instrumental as we continue our transformation and focus on building a new pipeline of innovative programs with the potential to become meaningful medicines.”","length":482,"tagName":"p"},{"type":"text","content":"Dawn Svoronos brings over 30 years of global biopharmaceutical experience, with a strong track record in c...